

Clinical Policy Title:	itraconazole
Policy Number:	RxA.284
Drug(s) Applied:	Sporanox®, Onmel™, Tolsura®
Original Policy Date:	02/07/2020
Last Review Date:	06/10/2021
Line of Business Policy Applies to:	All lines of business

Background

Itraconazole (Sporanox®, Onmel™, Tolsura®) is an azole antifungal agent. Onmel™ is indicated for the treatment of onychomycosis of the toenail caused by *Trichophyton rubrum* or *T. mentagrophytes*.

Sporanox® and Tolsura® capsules are indicated in:

- Immunocompromised and non-immunocompromised patients for the treatment of:
 - Blastomycosis, pulmonary and extrapulmonary
 - Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis
 - Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy

Sporanox® capsules are also indicated in:

- Non-immunocompromised patients for the treatment of:
 - Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium)
 - Onychomycosis of the fingernail due to dermatophytes (tinea unguium)

Sporanox® oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis.

Dosing Information

Drug Name	Indication	Dosing Regimen	Maximum Dose
Itraconazole (Sporanox®) capsule	Blastomycosis	200 mg PO once daily	400 mg/day
	Histoplasmosis	200 mg PO once daily	400 mg/day
	Aspergillosis	200 to 400 mg PO once daily	400 mg/day
	Onychomycosis	200 mg PO once daily (toenails with or without fingernail involvement) 200 mg PO BID for 1 week, followed by no drug for 3 weeks, then another week of 200 mg PO BID or 200 mg PO	400 mg/day

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

Dosing Information			
Drug Name	Indication	Dosing Regimen	Maximum Dose
		once daily for 6 weeks (fingernails only)	
Itraconazole (Sporanox®) capsule	In life-threatening situations	Loading dose of 200 mg PO TID given for the first 3 days of treatment	600 mg/day
Itraconazole (Sporanox®) oral solution	Oropharyngeal candidiasis	200 mg (20 mL) PO daily for 1 to 2 weeks; swish in the mouth (10 mL at a time) for several seconds and swallow	200 mg (20 mL)/day
	Esophageal candidiasis	100 mg (10 mL) PO daily for a minimum treatment of three weeks	200 mg (20 mL)/day
Itraconazole (Onmel™)	Onychomycosis	Toenail: 200 mg (one tablet) PO once daily for 12 consecutive weeks	200 mg/day
Itraconazole (Tolsura®)	Blastomycosis, Histoplasmosis	130 mg PO once daily. Increase dose if no obvious improvement or evidence of progressive fungal disease in 65 mg increments. Doses above 130 mg/day should be given in divided doses.	260 mg/day
	Aspergillosis	130 mg PO once daily or BID	260 mg/day

Dosage Forms

- Itraconazole (Sporanox®): Capsules 100 mg, Oral solution 10 mg/mL.
- Itraconazole (Onmel™): Tablets 200 mg.
- Itraconazole (Tolsura®): Capsules 65 mg.

Clinical Policy

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. The provision of provider samples does not guarantee coverage under the terms of the pharmacy benefit administered by RxAdvance. All criteria for initial approval must be met in order to obtain coverage.

I. Initial Approval Criteria

A. Onychomycosis (must meet all):

© 2021 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.

1. Request is for Sporanox® capsules or Onmel™ tablets (toenails only);
2. Member meets one of the following (a or b):
 - a. For fingernail disease: Failure of a 6-week trial of oral terbinafine at 250 mg/day, unless contraindicated or clinically significant adverse effects are experienced;
 - b. For toenail disease: Failure of a 12-week trial of oral terbinafine at 250 mg/day, unless contraindicated or clinically significant adverse effects are experienced;
3. Dose does not exceed (a or b):
 - a. Sporanox® capsules: 400 mg (4 capsules) per day;
 - b. Onmel™ tablets: 200 mg (1 tablet) per day.

Approval Duration

Commercial: Fingernail disease: 2 months; toenail disease: 3 months

Medicaid: Fingernail disease: 2 months; toenail disease: 3 months

B. Oropharyngeal Candidiasis (must meet all):

1. Diagnosis of oropharyngeal candidiasis;
2. Request is for Sporanox® oral solution;
3. Failure of a 14-day trial of nystatin suspension or clotrimazole troches/lozenges, unless contraindicated or clinically significant adverse effects are experienced;
4. Failure of a 14-day trial of fluconazole, unless contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed 200 mg (20 mL) per day.

Approval Duration

Commercial: 28 days

Medicaid: 28 days

C. Esophageal Candidiasis (must meet all):

1. Diagnosis of esophageal candidiasis;
2. Request is for Sporanox® oral solution;
3. Failure of a 21-day trial of fluconazole at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed 200 mg (20 mL) per day.

Approval Duration

Commercial: 28 days

Medicaid: 28 days

D. Aspergillosis (must meet all):

1. Diagnosis of aspergillosis;
2. Request is for Sporanox® or Tolsura® capsules;
3. Failure of a 3-month trial of voriconazole at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for voriconazole*
4. For Tolsura® requests, medical justification supports inability to use generic itraconazole capsules (e.g., contraindications to the excipients);
5. Dose does not exceed one of the following (a or b):
 - a. Sporanox®: 400 mg (4 capsules) per day;
 - b. Tolsura®: 260 mg (4 capsules) per day.

Approval Duration

Commercial: 3 months

Medicaid: 3 months

E. Blastomycosis or Histoplasmosis (must meet all):

1. Diagnosis of blastomycosis or histoplasmosis;
2. Request is for Sporanox® or Tolsura® capsules;
3. For Tolsura® requests, medical justification supports inability to use generic itraconazole capsules (e.g., contraindications to the excipients);
4. Dose does not exceed one of the following (a or b):
 - a. Sporanox®: 400 mg (4 capsules) per day;
 - b. Tolsura®: 260 mg (4 capsules) per day.

Approval Duration

Commercial: Blastomycosis: 6 months; Histoplasmosis: 42 days

Medicaid: Blastomycosis: 6 months; Histoplasmosis: 42 days

F. Hematologic Malignancy (off-label) (must meet all):

1. Diagnosis of hematologic malignancy;
2. Request is for Sporanox® or Tolsura®;
3. Member meets one of the following (a or b):
 - a. Request is for prophylaxis of aspergillosis;
 - b. Request is for prophylaxis of candidiasis, and member has failed fluconazole at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;
4. For Tolsura® requests, medical justification supports inability to use generic itraconazole capsules (e.g., contraindications to the excipients);
5. Dose does not exceed one of the following (a, b, or c):
 - a. Sporanox® capsules: 400 mg (4 capsules) per day;
 - b. Sporanox® oral solution: 200 mg (20 mL) per day;
 - c. Tolsura®: 260 mg (4 capsules) per day.

Approval Duration

Commercial: 3 months

Medicaid: 3 months

II. Continued Therapy Approval

A. Onychomycosis (must meet all):

1. Currently receiving medication that has been authorized by RxAdvance or member has previously met initial approval criteria listed in this policy;
2. Member is responding positively to therapy;
3. Member has not received more than 90 days of treatment;
4. If request is for a dose increase, new dose does not exceed (a or b):
 - a. Sporanox® capsules: 400 mg (4 capsules) per day;
 - b. Onmel™ tablets: 200 mg (1 tablet) per day.

Approval Duration

Commercial: Fingernail disease: 2 months; toenail disease: 3 months

Medicaid: Fingernail disease: 2 months; toenail disease: 3 months

B. Oropharyngeal/Esophageal Candidiasis (must meet all):

1. Currently receiving medication that has been authorized by RxAdvance or member has previously met initial approval criteria listed in this policy;
2. Member is responding positively to therapy;

3. Request is for Sporanox® oral solution;
4. If request is for a dose increase, new dose does not exceed 200 mg (20 mL) per day.

Approval Duration

Commercial: 14 days

Medicaid: 14 days

C. Blastomycosis, Histoplasmosis, or Aspergillosis (must meet all):

1. Currently receiving medication that has been authorized by RxAdvance or member has previously met initial approval criteria listed in this policy;
2. Member is responding positively to therapy;
3. Request is for Sporanox® or Tolsura® capsules;
4. If request is for a dose increase, new dose does not exceed one of the following (a or b):
 - a. Sporanox® capsules: 400 mg (4 capsules) per day;
 - b. Tolsura®: 260 mg (4 capsules) per day.

Approval Duration

Commercial: Blastomycosis: 6 months; Histoplasmosis: 42 days; Aspergillosis: 3 months

Medicaid: Blastomycosis: 6 months; Histoplasmosis: 42 days; Aspergillosis: 3 months

D. Hematologic Malignancy (off-label) (must meet all):

1. Currently receiving medication that has been authorized by RxAdvance or member has previously met initial approval criteria listed in this policy;
2. Request for Sporanox®;
3. Member is responding positively to therapy;
4. If request is for a dose increase, new dose does not exceed one of the following (a, b, or c):
 - a. Sporanox® capsules: 400 mg (4 capsules) per day;
 - b. Sporanox® oral solution: 200 mg (20 mL) per day;
 - c. Tolsura®: 260 mg (4 capsules) per day.
5. Diagnosis of onychomycosis;

Approval Duration

Commercial: 6 months

Medicaid: 6 months

III. Appendices

APPENDIX A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

CHF: Congestive heart failure

APPENDIX B: Therapeutic Alternatives

Below are suggested therapeutic alternatives based on clinical guidance. Please check drug formulary for preferred agents and utilization management requirements.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
terbinafine	250 mg PO once daily	500 mg per day
nystatin suspension	400,000 to 600,000 units (4 to 6 mL) per dose swished in the mouth QID	2.4 million units per day

clotrimazole troches/lozenges	10 mg troche PO 5 times daily for 14 days	Varies
fluconazole (Diflucan®)	400 mg PO per day	800 mg per day
voriconazole (Vfend®)	Weight ≥ 40 kg: 200 mg PO every 12 hours Weight < 40 kg: 100 mg PO every 12 hours	Weight ≥ 40 kg: 800 mg per day Weight < 40 kg: 400 mg per day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

APPENDIX C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Itraconazole should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF.
 - Concomitant coadministration of itraconazole with the following drugs: methadone, dofetilide, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), felodipine, pimozone, oral midazolam, triazolam, nisoldipine, cisapride, lovastatin, simvastatin.
 - Additional product-specific drug-drug interactions include:
 - Onmel™: levacetylmethadol (levomethadyl)
 - Sporanox®: (capsules and oral solution) and Tolsura®: disopyramide, dronedarone, irinotecan, lurasidone, ivabradine, ranolazine, eplerenone, ticagrelor, digoxin, isavuconazonium, naloxegol, lomitapide, avanafil, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, and solifenacin. Co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. Increased plasma concentrations of some of drugs due to co-administration of Tolsura® can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia.
 - Sporanox®: capsules: telithromycin, isavuconazole
 - Sporanox®: oral solution, levacetylmethadol (levomethadyl), isavuconazole
 - Pregnancy, or women contemplating pregnancy
 - Hypersensitivity to itraconazole
- Boxed Warning(s):
 - CHF or history of CHF (see contraindications)
 - Drug-drug interactions (see contraindications)

APPENDIX D: General Information

- Inform patients about the signs and symptoms of congestive heart failure. Instruct them to discontinue itraconazole and contact their healthcare provider immediately, if these signs or symptoms occur during treatment.

References

1. Sporanox® Oral Solution Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; September 2020. Available at: <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ae50721d-ee15-4ee7-9fe7-afd98c56461b&type=display>. Accessed Apr 14, 2021.

2. Sporanox® Capsules Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc., December 2019. Available at: <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a4d555fa-787c-40fb-bb7d-b0d4f7318fd0&type=display>. Accessed Apr 14, 2021.
3. Onmel™ Prescribing Information. Greensboro, NC: Merz Pharmaceuticals, LLC. November 2012. Available at: <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2&type=display>. Accessed Apr 14, 2021.
4. Tolsura® Prescribing Information. Greenville, NC: Mayne Pharma. June 2020. Available at: www.Tolsura.com. Accessed Apr 14, 2021.
5. Clinical Pharmacology [database online] powered by ClinicalKey. Tampa, FL: Elsevier, 2020. Accessed with subscription at: <http://www.clinicalkey.com>. Updated January 14, 2020. Accessed April 15, 2021.
6. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(12):1801. Accessed April 15, 2021.
7. Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Disease Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Accessed April 15, 2021.
8. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807. Accessed April 15, 2021.
9. Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Accessed April 15, 2021.
10. Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatology. 2014;171:937-58. Accessed April 15, 2021.
11. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073. Accessed April 15, 2021.
12. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed April 15, 2021.
13. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. Accessed April 15, 2021.
14. Itraconazole, Lexi-Drug. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Accessed with subscription at: <http://online.lexi.com>. Accessed April 15, 2021.

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established	01/2020	02/07/2020
Policy was reviewed: 1. Clinical Policy Title was updated. 2. Line of Business Policy Applies to was updated to “All lines of business”. 3. Initial and Continued approval duration was updated to include Medicaid, Commercial & HIM approval duration.	07/22/2020	09/14/2020

<ol style="list-style-type: none"> 4. Continued therapy criteria II.A.1, II.B.1, II.C.1 & II.D.1 was rephrased to “Currently receiving medication that has been authorized by RxAdvance...”. 5. Updated Appendix A: added CHF. 6. References were reviewed and updated. 		
<p>Policy was reviewed:</p> <ol style="list-style-type: none"> 1. Approval durations for HIM were removed. 2. Appendix B (Therapeutic Alternatives): Fixed header verbiage was updated as ‘Below are suggested therapeutic alternatives.’ Discontinued brands Lamisil®, and Mycelex® were removed. 3. Appendix C: Contraindication(s) was updated. 4. Appendix D: General Information was added. 5. References were updated. 	<p>04/15/2021</p>	<p>06/10/2021</p>